# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Based on positive biomarker results observed in adult cohort of Phase 2 clinical trial of ADX-629 in Sjögren-Larsson Syndrome, ...
As a result of the Exercise Period Extension, AbbVie may exercise the Option by delivering written notice to Aldeyra at any tim...
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational R...
CGEN: 240% | Compugen Says It Will Be Eligible To Receive $10M Milestone Payment Upon Dosing Of First Patient In AstraZeneca Ph...
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, Decem...
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ: ALDX) New Drug Application (NDA) of reprox...